Patients with neuroendocrine neoplasms (NENs) have heterogeneous somatostatin
receptor expression, with highly differentiated lesions having higher expression. Receptor …

Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine
neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect …

Purpose To evaluate the prognostic value of volumetric parameters calculated from 68 Ga-1,
4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-Thr 3-octreotate (68 Ga …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

We aimed to evaluate 68Ga-DOTATATE PET/CT for the early prediction of time to
progression and clinical outcome after a first cycle of peptide receptor radionuclide treatment …

Simple Summary The monitoring of disease in patients with neuroendocrine tumors is
challenging and requires specialized imaging techniques. To address these quests …

Purpose Precise determination of neuroendocrine tumor (NET) disease status and response
to therapy remains a rate-limiting concern for disease management. This reflects limitations …

Our objective was to evaluate the prognostic value of somatostatin receptor tumor burden on
68Ga-DOTATOC PET/CT in patients with well-differentiated (WD) neuroendocrine tumors …

Objectives To compare the diagnostic performance of 68 Ga-DOTATOC PET/MRI and 68 Ga-
DOTATOC PET/CT in the whole-body staging of patients with neuroendocrine tumours …

Despite the fact that several studies have been published regarding the prognostic factors of
neuroendocrine tumors (NETs), there are some cases in which available data are not …